CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Income (Loss) per Share (Tables)

3 Months Ended

Aug. 31, 2024


	Three months ended August 31,
(in thousands, except per share amounts)	2024		2023
Basic net income (loss) per share:
Net income (loss)	$	19,227	$	(11,571)
Less: Accrued preferred stock dividends		(372)		(373)
Net income (loss) applicable to common stockholders	$	18,855	$	(11,944)
Basic:
Weighted average common shares outstanding		1,135,043		923,587
Income (loss) per share	$	0.02	$	(0.01)
Diluted net income (loss) per share:
Net income (loss)	$	18,855	$	(11,944)
Reallocation of undistributed earnings as a result of conversion of preferred stock		372		—
Net income (loss) applicable to common stockholders	$	19,227	$	(11,944)

Number of shares used in basic computation		1,135,043		923,587
Weighted-average effect of dilutive securities
Warrant exercises		25,450		—
Preferred stock conversions		37,794		—
Diluted weighted average common shares outstanding		1,198,287		923,587
Diluted income (loss) per share	$	0.02	$	(0.01)


	Three months ended August 31,
(in thousands)	2024	2023
Stock options and warrants	232,597	276,503
Convertible notes	12,000	12,000
Convertible preferred stock	—	34,818
Reserved for issuance of common stock through a placement agent	—	14,663
Reserved for issuance of common stock related to note conversion	—	11,474